CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

The once-weekly insulin analog lowered A1c as effectively as once-daily formulations in three new trials in type 2 diabetes.

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...

Small, 3D-printed devices, designed to be implanted directly under the skin, could allow people with type 1 diabetes to ...

The liver is an attractive target organ for insulin gene expression in type 1 diabetes as it contains appropriate cellular mechanisms of regulated gene expression in response to blood glucose and ...

Novo Nordisk has developed a new version of the insulin analogue, called Fiasp, which added another DKK 1.6 billion to the fast-acting insulin pot last year and has patent protection to 2030.

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Public Citizen has been working with 100 health groups across Latin America to overcome the patent barrier, issuing multiple compulsory license requests and calling on governments to take action to ...

Insulin-producing human pancreas cells can be manufactured with 3D printers, researchers reported at the International Transplant Congress underway in London.

If long-acting PrEP uptake increased by 25%, however, new infections could be cut by more than half, with a 54% reduction across the cities studied. Current PrEP Options ...

NovoLog (insulin aspart) is a fast-acting insulin used for diabetes treatment. It’s injected 5 to 10 minutes before meals. It may be prescribed with other insulins or oral diabetes drugs.